Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03655691 · ClinicalTrials.gov registry record · Phase 2
ET-01 in Subjects With Lateral Canthal Lines, LCL-207
A Phase 2 study, sponsored by Eirion Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
NCT03655691: Completed Phase 2 study, sponsored by Eirion Therapeutics.
NCT03655691 is a Phase 2 study that has completed, run by Eirion Therapeutics. The registered enrollment target is 79 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03655691, a Phase 2 study, has completed, sponsored by Eirion Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
Study Summary
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
Primary Outcome
Investigators Global Assessment of the Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe). Response is defined as change by at least two ordinals from Baseline to Week 4.
Interventions
- BIOLOGICAL Vehicle
- BIOLOGICAL botulinum toxin, Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2018-08-16 |
| Est. Completion | 2019-04-11 |
| Phase | Phase 2 |
What the finished NCT03655691 record still lists
NCT03655691 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 79 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT03655691 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03655691 about?
NCT03655691 is a clinical study titled "ET-01 in Subjects With Lateral Canthal Lines, LCL-207". This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
What is the current status of trial NCT03655691?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2018-08-16. Estimated completion is 2019-04-11.
What interventions are being tested in trial NCT03655691?
The interventions under investigation include: Vehicle (BIOLOGICAL), botulinum toxin, Type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT03655691?
This trial is sponsored by Eirion Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03655691's enrollment target sits among peer trials
79 884th of 2000 higher than 1,117 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05798897 · 79 participants · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI